Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Musc Foundation for Research Development has 6 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 6 distinct examiners and 6 distinct art units, indicating that each pending matter is associated with a separate examiner and technical assignment. This structure limits the value of a single portfolio-wide response approach and favors matter-level docketing, claim review, and prior-art analysis.
COUNTS, GARY W is the busiest examiner, with 1 pending action. No examiner has a larger recorded pending-action concentration, so counsel should not assume that one examiner’s treatment will govern the other matters. Consistent technology positioning can still support coordinated review, but office-action responses should reflect each assigned examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUNTS, GARY W | 1 | 58.9% | +29.7% |
| EDWARDS, PHILIP CHARLES | 1 | 85.0% | +15.5% |
| PAULUS, ERIN VIRGINIA | 1 | 20.0% | +94.1% |
| NGUYEN, HUONG Q | 1 | 46.2% | +44.4% |
| HIRAKIS, SOPHIA P | 1 | 57.4% | +69.8% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 78d overdue |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 29d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 78d overdue |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 29d overdue |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 29d overdue |
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | COUNTS, GARY W | — |
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | — |
| 17279857 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| 3792 | 1 |
| 1631 | 1 |
| 3791 | 1 |
| 1623 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | COUNTS, GARY W | 1678 | §102§103§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | 3792 | §103 | Final Rejection | — | Pending | Aug 25, 2023 |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | 29d overdue | Pending | Mar 31, 2023 |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 3791 | §103 | Non-Final OA | 29d overdue | Pending | Mar 28, 2023 |
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 1623 | §102§103§112 | Final Rejection | 78d overdue | Pending | Jan 17, 2023 |
| 17279857 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | DEBERRY, REGINA M | 1647 | DP | Final Rejection | — | Pending | Mar 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMusc Foundation for Research Development has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Gary W Counts has the most, with 1 of Musc Foundation for Research Development's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
